<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00771420</url>
  </required_header>
  <id_info>
    <org_study_id>CAM-3001-0702</org_study_id>
    <nct_id>NCT00771420</nct_id>
  </id_info>
  <brief_title>A Single Dose Study of the CAM-3001 in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CAM-3001 in Patients With Rheumatoid Arthritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate safety and tolerability of the escalating dose of CAM-3001 in patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the safety and tolerability of escalating single doses of CAM-3001 in patients&#xD;
      with RA; To investigate the pharmacokinetics of single doses of CAM-3001 in RA patients; To&#xD;
      investigate the pharmacodynamics of single doses of CAM-3001 in RA patients; To investigate&#xD;
      the preliminary clinical effects of CAM-3001 on the signs and symptoms of RA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events • Changes in vital signs, ECG, lung function tests and clinical laboratory values</measure>
    <time_frame>End of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of CAM-3001 will be calculated and tabulated descriptively for each dose group:</measure>
    <time_frame>Day 28 post infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.01mg/kg and 0.03mg/kg CAM-3001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1mg/kg CAM-3001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.3mg/kg CAM-3001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.0mg/kg CAM-3001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3.0mg/kgCAM-3001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10.0mg/kg CAM-3001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAM-3001</intervention_name>
    <description>A single patient shall be dosed with a dose of 0.01mg/kg of CAM-3001 followed no sooner than 24 hours later by a second patient at a dose of 0.03mg/kg.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Mavrilimumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAM-3001</intervention_name>
    <description>Dosed at 0.1mg/kg.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Mavrilimumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAM-3001</intervention_name>
    <description>Dosed at 0.3mg/kg</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Mavrilimumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAM-3001</intervention_name>
    <description>Dosed at 1.0 mg/kg.</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Mavrilimumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAM-3001</intervention_name>
    <description>Dosed at 3.0 mg/kg.</description>
    <arm_group_label>5</arm_group_label>
    <other_name>Mavriliumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAM-3001</intervention_name>
    <description>Dosed at 10 mg/kg.</description>
    <arm_group_label>6</arm_group_label>
    <other_name>Mavrilimumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Active: Placebo 5:1 for arms 2-6</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated informed consent, prior to any study related procedures&#xD;
&#xD;
          -  Male and female patients aged 18-70 years at the screening visit&#xD;
&#xD;
          -  Use of an appropriate method of contraception&#xD;
&#xD;
          -  A diagnosis of adult onset rheumatoid arthritis of at least 6 months duration as&#xD;
             defined by the 1987 ACR classification criteria - ACR functional class I, II or III&#xD;
&#xD;
          -  Treatment with methotrexate for at least 3 months and stable dose 10mg - 25mg / week&#xD;
             for ≥ 8 weeks prior to the baseline visit&#xD;
&#xD;
          -  Availability of clear chest X-ray (i.e. no evidence of TB, chest infection or cardiac&#xD;
             failure). Patients who are clinically asymptomatic with minor changes consistent with&#xD;
             rheumatoid lung are acceptable.&#xD;
&#xD;
          -  Stable mild or inactive rheumatoid arthritis where in the opinion of the investigator&#xD;
             it is unlikely that a change in the patient's therapeutic regimen would be required&#xD;
             during the subsequent 3 months.&#xD;
&#xD;
          -  DAS28 ≤ 4.8 for at least 3 months prior to the baseline visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Relating to RA&#xD;
&#xD;
          -  Diagnosis of any other inflammatory arthritis (e.g. psoriatic arthritis or ankylosing&#xD;
             spondylitis), or a diagnosis of a secondary, non-inflammatory type of arthritis (e.g.&#xD;
             osteoarthritis or fibromyalgia) that in the Investigator's opinion is symptomatic&#xD;
             enough to interfere with the evaluation of the effect of CAM-3001 on the patient's&#xD;
             primary diagnosis of rheumatoid arthritis Relating to Previous Clinical Trials and&#xD;
             Biologic Therapies&#xD;
&#xD;
          -  Administration of any investigational or experimental non-biologic therapy in the 12&#xD;
             weeks prior to the baseline visit&#xD;
&#xD;
          -  Administration of any biologic therapy within 6 months prior to the baseline visit&#xD;
             Relating to Concomitant Medications&#xD;
&#xD;
          -  Use of prohibited concomitant medications, which might confound the interpretation of&#xD;
             the study data Relating to Medical History&#xD;
&#xD;
          -  Female patients who are pregnant or breast-feeding, or who plan to become pregnant&#xD;
             during the trial or during the 24 weeks after administration of CAM-3001&#xD;
&#xD;
          -  Male or female patients not willing to use reliable methods of birth control for the&#xD;
             duration of the study&#xD;
&#xD;
          -  A history of TB, or clinical/radiographic evidence of TB, or positive TB test&#xD;
&#xD;
          -  A history or current symptoms and signs of chronic infection, or recent (within 6&#xD;
             months prior to screening visit) serious infection including herpes zoster&#xD;
&#xD;
          -  Patients at a high risk of infection e.g. a history of an infected joint prosthesis at&#xD;
             any time with that prosthesis still in situ, leg ulcers, indwelling urinary catheter,&#xD;
             persistent or recurrent chest infections&#xD;
&#xD;
          -  Neutrophil count &lt; 1000 x 106 cells/L&#xD;
&#xD;
          -  A positive hepatitis B surface antigen test and/or hepatitis C antibody test result&#xD;
&#xD;
          -  A positive test for human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Receipt of live (attenuated) vaccine within the 4 weeks prior to baseline or during&#xD;
             the study&#xD;
&#xD;
          -  Current or recent history of significant renal, hepatic, haematological, immunological&#xD;
             (other than RA), gastrointestinal, endocrine, pulmonary, cardiac, neurological, or&#xD;
             cerebral disease which would interfere with the patient's participation in the trial.&#xD;
             Patients with mild and stable asthma or mild and stable Chronic Obstructive Pulmonary&#xD;
             Disease (COPD) may be included at the discretion of the Investigator&#xD;
&#xD;
          -  Active malignancy or lymphoproliferative disorder of any type, or a history of&#xD;
             malignancy except for basal cell carcinoma of the skin that has been excised prior to&#xD;
             the screening visit&#xD;
&#xD;
          -  Suspected alcohol or substance abuse&#xD;
&#xD;
          -  Donation of ≥ 400mL of blood within 8 weeks prior to baseline&#xD;
&#xD;
          -  Any other significant medical condition which in the opinion of the investigator might&#xD;
             increase the risk to the patient or confound the interpretation of the data&#xD;
&#xD;
          -  Individuals who are legally institutionalised&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ehsanollah Esfandiari, PhD MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite Research Organization GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>October 10, 2008</study_first_submitted>
  <study_first_submitted_qc>October 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2008</study_first_posted>
  <last_update_submitted>July 19, 2012</last_update_submitted>
  <last_update_submitted_qc>July 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mavrilimumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

